Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Inventory (2017 - 2023)

Avalo Therapeutics (AVTX) has disclosed Inventory for 7 consecutive years, with $18000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Inventory fell 21.74% year-over-year to $18000.0, compared with a TTM value of $18000.0 through Jun 2023, down 21.74%, and an annual FY2022 reading of $20000.0, down 47.37% over the prior year.
  • Inventory was $18000.0 for Q2 2023 at Avalo Therapeutics, down from $19000.0 in the prior quarter.
  • Across five years, Inventory topped out at $1.0 million in Q1 2019 and bottomed at $3000.0 in Q4 2020.
  • Average Inventory over 5 years is $107007.2, with a median of $20000.0 recorded in 2021.
  • The sharpest move saw Inventory plummeted 98.45% in 2020, then surged 1166.67% in 2021.
  • Year by year, Inventory stood at $21334.0 in 2019, then tumbled by 85.94% to $3000.0 in 2020, then soared by 1166.67% to $38000.0 in 2021, then crashed by 47.37% to $20000.0 in 2022, then dropped by 10.0% to $18000.0 in 2023.
  • Business Quant data shows Inventory for AVTX at $18000.0 in Q2 2023, $19000.0 in Q1 2023, and $20000.0 in Q4 2022.